EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical perspective and treatment of immune-related colitis after cancer immunotherapy

Lukas M Braun, Yunjie Lu, Robert Zeiser

Trends in Cancer · 2025-11 · 11 (11) · 1058-1077

DOI: 10.1016/j.trecan.2025.07.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-11. Verfasst von Lukas M Braun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Ca…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Colitis, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Deutsche Krebshilfe, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting negative regulators of immunity with immune-checkpoint inhibitors (ICIs) has led to significant survival benefit in patients with various cancer entities. ICI therapy disrupts mechanisms of immune tolerance, which induces inflammatory toxicities in different target organs, summarized as immune-related adverse events (irAEs) in some patients. ICI-colitis relies on the activation of intestinal tissue-resident memory T cells (TRM cells) and is one of the most frequently observed immune-related toxicities; it can be fatal if untreated. The disease is associated with highly cytotoxic intestinal T cells and inflammatory myeloid activation. Current clinical management relies on broad immunosuppression, potentially reducing antitumor immunity. Ideal future therapies for irAEs will uncouple immunosuppressive activities in the inflamed target organ and the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsColitisImmunotherapyHumansTumor MicroenvironmentImmune Tolerance

Stichwörter der Autor:innen

anticancer immunitycancer immunotherapycheckpoint blockadecolitisimmune-checkpoint inhibitorimmune-related adverse eventsimmune-related colitisinflammatory toxicities

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between D…
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

Förderung

  • European Research Council
  • Deutsche Krebshilfe
  • Leukemia and Lymphoma Society
  • European Commission
  • Deutsche Forschungsgemeinschaft
  • Deutschen Konsortium für Translationale Krebsforschung
  • José Carreras Leukämie-Stiftung

Zitieren

APA

Braun, L. M., Lu, Y., & Zeiser, R. (2025). Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. Trends in Cancer, 11(11), 1058-1077. https://doi.org/10.1016/j.trecan.2025.07.005

Vancouver

Braun LM, Lu Y, Zeiser R. Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. Trends in Cancer. 2025;11(11):1058-1077. doi:10.1016/j.trecan.2025.07.005

BibTeX
@article{Braun2025,
  author = {Braun, Lukas M and Lu, Yunjie and Zeiser, Robert},
  title = {Clinical perspective and treatment of immune-related colitis after cancer immunotherapy},
  journal = {Trends in Cancer},
  year = {2025},
  volume = {11},
  number = {11},
  pages = {1058--1077},
  doi = {10.1016/j.trecan.2025.07.005}
}
Kostenlos starten →